Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 38, Issue 11, 2011, Pages 2346-2354

  Matsudaira, Ran ^a   Tamura, Naoto ^a   Sekiya, Fumio ^a   Ogasawara, Michihiro ^a   Yamanaka, Kenjiro ^b   Takasaki, Yoshinari ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b SASAKI INSTITUTE   (Japan)

Author keywords

Anti Ro SSA antibodies; Autoantibodies; Infliximab; Rheumatoid arthritis; Tumor necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; RO ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; LOGISTIC MODELS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80155126086     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.101295     Document Type: Article

References (36)

1. Katchamart W, Johnson S, Lin H, Phumethum V, Salliot C, Bombardier C. Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care Res 2010;62:1128-43.
2. van der Helm-van Mil A, Verpoort K, Breedveld F, Toes R, Huizinga T. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2006;7:R949-58.
3. Syverson S, Gaarder P, Goll G, Ødegård S, Haavardsholm E, Mowinckel P, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008;67:212-7. (Pubitemid 351183310)
4. Szodoray P, Szabó Z, Kapitány A, Gyetvai A, Lakos G, Szántó S, et al. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2010;9:140-3.
5. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys E, De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005;52:2192-201. (Pubitemid 40994342)
6. Eriksson C, Engstrand S, Sundqvist K, Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2006;64:403-7.
7. Bacquet-Deschryver H, Jouen F, Quillard M, Ménard J, Goëb V, Lequerré T, et al. Impact of three anti-TNF alpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol 2008;28:445-55.
8. Franceschini F, Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 2005;38:55-63. (Pubitemid 40515004)
9. Buyon J, Clancy R. Maternal autoantibodies and congenital heart block: mediators, markers, and therapeutic approach. Semin Arthritis Rheum 2003;33:140-54. (Pubitemid 38030078)
10. Schneeberger E, Citera G, Heredia M, Maldonado Cocco J. Clinical significance of anti-Ro antibodies in rheumatoid arthritis. Clin Rheumatol 2008;27:517-19.
11. Cavazzana I, Franceschini F, Quinzanini M, Manera C, Del Papa N, Maglione W, et al. Anti-Ro/SSA antibodies in rheumatoid arthritis: clinical and immunologic associations. Clin Exp Rheumatol 2006;24:59-64.
12. Bathon J, Cohen S. The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road. Arthritis Rheum 2008;59:757-9. (Pubitemid 351847557)
13. Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
14. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8. (Pubitemid 34539104)
15. Bouffard P, Laniel MA, Boire G. Anti-Ro (SSA) antibodies: clinical significance and biological relevance. J Rheumatol 1996;23:1838-41.
16. Ben-Chetrit E. The molecular basis of the SSA/Ro antigens and clinical significance of their antibodies. Br J Rheumatol 1993;32:396-402. (Pubitemid 23181993)
17. De Vlam K, De Keyser F, Verbruggen G, Vandenbossche B, Vanneuville B, D'Haese D, et al. Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol 1993;11:393-7. (Pubitemid 23287160)
18. Fernandez SA, Lobo AZ, Oliveira ZN, Fukumori LM, Périgo AM, Rivitti EA. Prevalence of antinuclear autoantibodies in the serum of normal blood donors. Rev Hosp Clin Fac Med Sao Paulo 2003;58:315-9.
19. Akaike H. A new look at the statistical model identification. IEEE Trans Automatic Control 1974;19:716-23.
20. Boire G, Ménard HA. Clinical significance of anti-Ro (SSA) antibody in rheumatoid arthritis. J Rheumatol 1988;15:391-4.
21. Boire G, Ménard HA, Gendron M, Lussier A, Myhal D. Rheumatoid arthritis: anti-Ro antibodies define a non-HLA-DR4 associated clinicoserological cluster. J Rheumatol 1993;20:1654-60. (Pubitemid 24017564)
22. Simmons-O'Brien E, Chen S, Watson R, Antoni C, Petri M, Hochberg M, et al. One hundred anti-Ro (SS-A) antibody positive patients: a 10-year follow-up. Medicine 1995;74:109-30.
23. Cavazzana I, Bobbio-Pallavicini F, Franceschini F, Bazzani C, Ceribelli A, Bravi E, et al. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients. Clin Exp Rheumatol 2007;25:676-83. (Pubitemid 350284839)
24. Moutsopoulos HM, Skopouli FN, Sarras AK, Tsampoulas C, Mavridis AC, Constantopoulos SH, et al. Anti-Ro (SSA) positive rheumatoid arthritis (RA): a clinicoserological group of patients with high incidence of D-penicillamine side effects. Ann Rheum Dis 1985;44:215-9. (Pubitemid 15112833)
25. Drosos AA, Lanchbury JS, Panayi GS, Moutsopoulos HM. Rheumatoid arthritis in Greek and British patients. Arthritis Rheum 1992;35:745-8.
26. Morozzi F, Bellisai F, Simpatico A, Pucci G, Bacarelli MR, Campanella V, et al. Comparison of different methods for the detection of anti-Ro/SSA antibodies in connective tissue diseases. Clin Exp Rheumatol 2000;18:729-31.
27. Skopouli FN, Andonopoulos A, Moutsopoulos HM. Clinical implications of the presence of anti-Ro (SSA) antibodies in patients with rheumatoid arthritis. J Autoimmun 1988;4:381-8.
28. Tishler M, Golbrut B, Shoenfeld Y, Yaron M. Anti-Ro (SSA) antibodies in patients with rheumatoid arthritis - a possible marker for gold induced side effects. J Rheumatol 1994;21:1040-2. (Pubitemid 24182274)
29. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004;6:R264-72.
30. Allanore Y, Sellam J, Batteux F, Job Deslandre C, Weill B, Kahan A. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol 2004;22:756-8. (Pubitemid 40045539)
31. Elkayam O, Burke M, Vardinon N, Zakut V, Yitzhak R, Paran D, et al. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity 2005;38:155-60. (Pubitemid 40872740)
32. Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet J. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy. J Rheumatol 2006;33:24-30. (Pubitemid 43054275)
33. Via C, Shustov A, Rus V, Lang T, Nguyen P, Finkelman F. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001;167:6821-6. (Pubitemid 33144173)
34. Bell D, Morrison B. The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro. Clin Immunol Immunopathol 1991;60:13-26.
35. Ferraro-Peyret C, Coury F, Tebib J, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two year prospective study. Arthritis Res Ther 2004;6:R535-43.
36. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-alpha agents. Ann NY Acad Sci 2005;1051:559-69.